Videos
VIDEO: Prof Stephen Nicholls Targeting PCSK9 inhibitors to the right patient
read more »
VIDEO: Prof Stephen Nicholls Effect of alirocumab on MI types
read more »
VIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids
Results from the BANTING study add to the evidence-base that PCSK9 inhibition is efficacious in improving lipid goal attainment in individuals with type 2 diabetes mellitus (T2DM) with hypercholesterolaemia or mixed dyslipidaemia. There were also favourable changes in postprandial lipids. Dyslipidaemia is one of the…
read more »
VIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points
Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital, London UK): A view of the AHA/ACC 2018 Cholesterol Guidelines The recent update to the AHA/ACC 2018 Cholesterol Guidelines has created much debate. Here, PCSK9 Forum Editor Professor Anthony Wierzbicki gives his view on one of the…
read more »
VIDEO: Coronary artery calcium for stratifying risk in familial hypercholesterolaemia
Professor Raul Santos (Hospital Israelita Albert Einstein and University of São Paulo, Brazil): Is coronary artery calcium a tool for stratifying risk in familial hypercholesterolaemia? Professor Raul Santos discusses this pertinent question in the light of results from a recent cohort study in more than…
read more »
VIDEO: PCSK9 Forum Inhibitors and Health Economics
The value of therapeutic intervention with a PCSK9 inhibitor is highly pertinent with increasingly finite resources for healthcare services. While PCSK9 inhibitors are undoubtedly extremely powerful LDL-lowering therapies that reduce cardiovascular events, their perceived cost has been a major barrier to uptake. The recent ODYSSEY…
read more »
VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study
read more »
VIDEO: New insights from ODYSSEY OUTCOMES
read more »
VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)
Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a). Now the…
read more »
VIDEO: Why we need to avoid recurrent events: Plaque biology considerations
read more »
REDUCE-IT- does the formulation matter?
read more »
REDUCE-IT take home messages
read more »
More guideline controversy
read more »
Are we ready to test the lipoprotein(a) hypothesis
read more »
AHA 2018 ODYSSEY Alternative Extension Trial
read more »
VIDEO: AHA 18 ODYSSEY OUTCOMES Take Home Messages from Total Events Analysis
read more »
AHA 2018 ODYSSEY OUTCOMES Total Events Analysis
read more »
VIDEO: AHA 2018 US Cholesterol Guidelines
read more »
